PITTSBURGH, May 6, 2019 /PRNewswire/ — An inventor from Fresno, Calif., has developed the patent pending VIANKABIT, a wearable fitness tracker device that also allows a pregnant woman to monitor the fetal heartbeat.
“A family member lost an unborn child. Had the mother been able to monitor the baby’s heartbeat earlier, it may have been prevented,” said the inventor. The VIANKABIT offers a convenient way to monitor a fetal heartbeat. It also allows a pregnant woman to track her own heart rate. It eliminates the need to go to a doctor to check a fetal heartbeat. This device also alleviates worry about a baby’s well-being. The device is convenient and easy to use, and it may provide peace of mind and reassurance to expectant mothers. It is producible as an all-in-one unit or as an accessory/add-on to standard fitness trackers.
The original design was submitted to the Fresno sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 18-FRO-685, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp’s Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/inventhelp-inventor-develops-fitnessheartbeat-tracker-for-pregnant-women-fro-685-300843792.html
SOURCE InventHelp
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…